- Home
- ACIU vs LYEL Comparison
ACIU vs LYEL Comparison
Compare ACIU & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- LYEL
- Stock Information
- Founded
- ACIU 2003
- LYEL 2018
- Country
- ACIU Switzerland
- LYEL United States
- Employees
- ACIU N/A
- LYEL N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- LYEL Health Care
- Exchange
- ACIU Nasdaq
- LYEL Nasdaq
- Market Cap
- ACIU 213.3M
- LYEL 207.7M
- IPO Year
- ACIU 2016
- LYEL 2021
- Fundamental
- Price
- ACIU $2.04
- LYEL $11.08
- Analyst Decision
- ACIU Strong Buy
- LYEL Sell
- Analyst Count
- ACIU 1
- LYEL 2
- Target Price
- ACIU $12.00
- LYEL $15.00
- AVG Volume (30 Days)
- ACIU 109.7K
- LYEL 29.1K
- Earning Date
- ACIU 08-05-2025
- LYEL 08-12-2025
- Dividend Yield
- ACIU N/A
- LYEL N/A
- EPS Growth
- ACIU N/A
- LYEL N/A
- EPS
- ACIU N/A
- LYEL N/A
- Revenue
- ACIU $36,362,036.00
- LYEL $60,000.00
- Revenue This Year
- ACIU N/A
- LYEL N/A
- Revenue Next Year
- ACIU $1,022.98
- LYEL N/A
- P/E Ratio
- ACIU N/A
- LYEL N/A
- Revenue Growth
- ACIU 86.71
- LYEL 11.11
- 52 Week Low
- ACIU $1.43
- LYEL $7.65
- 52 Week High
- ACIU $3.98
- LYEL $32.00
- Technical
- Relative Strength Index (RSI)
- ACIU 44.83
- LYEL 53.12
- Support Level
- ACIU $2.05
- LYEL $10.56
- Resistance Level
- ACIU $2.19
- LYEL $11.67
- Average True Range (ATR)
- ACIU 0.11
- LYEL 0.62
- MACD
- ACIU -0.01
- LYEL -0.01
- Stochastic Oscillator
- ACIU 4.55
- LYEL 75.31
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.